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Endovascular brachytherapy after percutaneous coronary intervention (PCI), is becoming a standard approach 
for the treatment and prevention of restenosis. A variety of technical approaches are currently available to deliver 
ionizing irradiation to the vascular target. Basically two kinds of radioactive isotopes are available that emit 
gamma radiation (photons) or beta radiation (electrons). The pitfalls and solutions for the optimization of 
dosimetry are discussed. As might be expected, the inhomogeneous dose distribution across the target volume 
results in recurrence by underdosage or in complications because of overdosage. Moreover, uniformization of the 
target definition and reporting of the dose distribution in endovascular brachytherapy is a prerequisite for 
comparison between the results of the various clinical trials and is absolutely necessary to improve the therapeutic 
efSicacy of this new approach in the prevention of restenosis after coronary angioplasty with or without stenting. 
(J Interven Cardiol2000; 13:425430) 
Introduction 
Cardiovascular disease is one of the leading causes 
of death in developed countries. It is characterized by 
a vascular stenosis process that is multifactorial in its 
origin. Andreas Griintzig introduced the technique of 
percutaneous transluminal coronary angioplasty 
(PTCA) in 1977 to complement the only available 
revascularization technique at that time, the coronary 
bypass. However, the long-term vascular efficacy of 
PTCA is reduced by the occurrence of restenosis in the 
dilated segment.z4 This vascular restenosis is known 
to be due to several mechanisms: elastic recoil of the 
artery immediately post-PTCA, negative vascular re- 
modeling, thrombus formation at the site of the injured 
vessel, excessive healing with neointimal prolifera- 
tion, and matrix deposition resulting in a hypertrophic 
A variety of therapeutic approaches to pre- 
vent restenosis after revascularization have been 
tested. One of these approaches is the use of stents that 
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are designed to reduce the elastic recoil and the nega- 
tive remodeling, but obviously the use of stents does 
not influence the neointimal cellular proliferation and 
matrix synthesis.'&I2 Moreover, it has been shown in 
experimental animal models and in the clinical setting 
that this healing process is even stimulated by the use 
of stents resulting in persisting restenosis rates in 
about 30% of the cases.235,6,10,13-17 Until recently pub- 
lished none of the pharmaceutical ap- 
proaches tested resulted in the same reduction in the 
rate of vascular stenosis as the one observed after en- 
dovascular brachytherapy, especially for in-stent 
restenosis. The use of ionizing irradiation for benign 
diseases is not a new concept.*' It is currently well 
known that radiotherapy is able to block benign prolif- 
erative disorders like keloid formation. The restenosis 
can also be considered, at least in part, as an uncon- 
trolled proliferative process and as such it can be po- 
tentially inhibited by ionizing irradiation. 
To deliver the radiation dose to the target vessel, 
sealed sources (solid or liquid) have been developed 
and are considered as the preferred treatment ap- 
proach, although some research teams are working on 
the use of external irradiation to prevent restenosis, es- 
pecially in peripheral artery diseasesz1-" or on the use 
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of “soft” X rays endoluminally. Two kinds of isotopes 
are available for the sealed sources: gamma and beta 
emitters. The ideal source to be used in endovascular 
brachytherapy should be a source with a high specific 
activity, a long half-life, and yielding a dose distribu- 
tion as uniform as possible over a distance of 2-3 mm. 
Some of the problems related to the definition of target 
volume, to dose prescription, and the published trials 
concerning endovascular brachytherapy are discussed 
in this article. 
Dosimetric Requirements and Choice of the 
Isotope 
The dosimetric requirements for intraluminal treat- 
ment are listed in Table 1. None of the sources avail- 
able for endovascular brachytherapy completely meet 
all the requirements. Iridium ( 19*Ir) sources (photons) 
have the disadvantage of a high “integral dose” be- 
cause of the higher penetration in the surrounding nor- 
mal tissues. The use of isotopes like 1921r present radi- 
ation safety problems for the patient (whole body 
dose) and attending staff, and most catheterization lab- 
oratories are not equipped for these high activity 
sources (around 10 Curie = Ci). Beta sources such as 
strontium (90Sr) and yttrium (90Y) have the advantage 
of reducing the integral dose to the normal tissues of 
the patient and do not represent a radiation safety prob- 
lem for the attending catheterization laboratory staff. 
These beta sources with modest activities (150-300 
mCi) are able to provide high dose rates (short dwell 
times), and do not require supplementary radiation 
Table 1. The Dosimetric Requirements for Intraluminal Treatment 
1. The single fraction acute dose should be 15-20 Gy applied to a 
length of 2-3 cm of arterial wall, approximately 2-5 mm in di- 
ameter and 0.5-mm thick. 
2. The high dose volume should be tightly confined to the region of 
angioplasty with a minimum dose to normal vessels and 
myocardium. 
3. The dose rate should be > 5 Gylmin to keep treatment times 
< 5 minutes to reduce the risk of thrombosis other cardiac com- 
plications. 
4. The radioactive source should have physical properties suitable 
for endovascular applications through angioplasty catheters (di- 
mensions, stiffness, flexibility). 
Modified from H.I. Amok, J. Weinberger in Vascular Brachyrher- 
upy, R. Waksman, ed. the Netherlands; IR Crocker & RF Mould. 
Pub. Nucletron B. V., 1996. 
safety procedures other than those already available in 
any catheterization laboratory. However, the dose 
falloff in the tissue is much steeper compared to 
gamma radiation, resulting in a higher dose inhomo- 
geneity between the endoluminal surface and the ad- 
ventitial surface, especially for pure beta emitters. This 
inhomogeneity can have long-term deleterious effects 
because at these high doses of irradiation close to the 
source, definitive radiation damage may occur at the 
endovascular surface, predisposing to thrombus for- 
mation. Beta emitters such as 90Y and phosphorus 
(32P) have the practical disadvantage of a short half- 
life (64 hours and 14.3 days, respectively) compared to 
the gamma emitter ‘921r (74 days). However, the 
9oSrp0Y beta source is an interesting alternative as a 
beta-emitting isotope because it has a half-life of 28 
years. 
International Commission on Radiation Units 
and Measurements Report 58 and Vascular 
Brachytherapy 
The International Commission on Radiation Units 
and Measurements (ICRU) has developed “interna- 
tionally accepted recommendations regarding quanti- 
ties and units of radiation and radioactivity, proce- 
dures suitable for measurement and application of 
these quantities, and physical data needed in the appli- 
cation of these procedures, the use of which tends to 
assure uniformity in reporting.” According to these 
recommendations collected in ICRU Report 58, a dis- 
tinction has to be made between “temporary” and 
“permanent” implants. It is obvious that in the case of 
vascular brachytherapy we are dealing with temporary 
implants because the source is removed after the dose 
delivery, an exception being the radioactive im- 
plantable stents. For the clarity of the subsequent dis- 
cussion, only the dosimetry problems related to sealed 
sources and not the radioactive stents are discussed. 
The totai time of the “implantation” (= dwell time) 
in temporary implants depends on the number of 
sources, their strength, and pattern of implantation. In 
vascular brachytherapy, we are dealing with a source 
pattern, which is a “single plane” implant, in which 
improvement of the dose distribution is possible 
through modulation of the dwell time. The activity of 
the source should be expressed in Reference Air 
Kerma rate (KERMA = Kinetic Energy Released in 
Material) (unit = mGy.h-’ at one meter), but in general 
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and in most of the papers related to endovascular 
brachytherapy, the activity of the source is reported as 
the number of disintegrations per time unit expressed 
in Curie (1 Ci = 3.7.10’’ disintegrations per second). 
The official unit, however, should be the Becquerel (1 
Bq = 2.703.10-” Ci), and in theory the Ci has not been 
used since 1985. 
As it is the case for external radiotherapy in oncol- 
ogy, the ICRU has defined volumes to be used for “in- 
terstitial” therapy. By analogy gross tumor volume 
(GTV) could be replaced by vascular stenosis volume 
(VSV), which can be further subdivided in different 
volumes as proposed by Carlier et al. The clinical tur- 
get volume (CTV) should be the tissue volume con- 
taining the VSV and the volume injured by the angio- 
plasty procedure and stenting. The planning target 
volume (PTV) is the volume to be irradiated to make 
sure that the CTV receives a therapeutic dose, and 
therefore, it contains a safety margin dependent on the 
isodose distribution characteristic for the source train 
used. Finally, the treated volume (TV) is the volume 
receiving a minimum target dose that is deemed nec- 
essary to achieve the treatment goal. 
The volume definitions proposed by the ICRU 
should be used as these definitions are universally ac- 
cepted and are also used in radiation oncology. The 
problem of definition of the target and the prescription 
and reporting of the dose in endovascular brachyther- 
apy is fundamentally the same as the one encountered 
in radiation-oncology and, therefore, the same rules 
should be applied. The aim of the treatment team is to 
apply a dose distribution as uniform as possible to a 
“volume at risk” to develop restenosis after PTCA 
with or without stenting. This should be a three-di- 
mensional approach and not a “vascular segment” seen 
on angiography that is only a reductive two-dimen- 
sional approach. A lot of attention is dedicated to cor- 
rect longitudinal coverage of the CTV, as it has been 
shown that vessel wall injury, concomitantly to low 
dose irradiation results in an increase of stenosis at the 
In most of the papers published on the subject of en- 
dovascular brachytherapy, there is no homogeneous 
way of defining the target volumes and no uniform 
way of dose prescription and reporting. It must be em- 
phasized that this is important for the analysis and es- 
pecially the comparison of the success rate and com- 
plication rate between different clinical trials in which 
often various irradiation techniques have been used. 
For the success rate, we are basically interested in 
whether the target volume received an adequate dose 
and if there is no “edge effect” (due to the isodose con- 
figuration at both extremities of the source train) or 
“geographical miss” (due to insufficient covering of 
the volume to be For the complication 
rate, it is going to be important to correlate irradiated 
volume of healthy tissues surrounding the target vessel 
to risk of complications as beta and gamma radiation 
yield a complete different integral dose. 
The Dose Distribution and Dose Volume 
Histogram Concept 
Accurate dosimetry requires the introduction of pa- 
rameters allowing a good evaluation of the geometry 
of the target. This implies not only a knowledge of the 
configuration of the target in its longitudinal direction 
(i.e., the total length of the injured vessel as seen on an- 
g i ~ g r a p h y ) , ~ ~ , * ~  but also its radial distribution along 
this longitudinal axis (i.e., the depth of the target at any 
segment of the v e ~ s e l ) . ~ ~ , ~ ~  The Rotterdam group3’ 
proposed using constant step pullback intravascular 
ultrasound (IVUS) controlled by the electrocardio- 
graphic trigger algorithm to avoid alteration of the ul- 
trasonographic imaging by the movement of the heart. 
This technique allows the description of the cumula- 
tive dose-volume frequency distribution (known as the 
dose volume histogram [DVH]) over three specific 
volumes: (1) the luminal surface volume with a thick- 
ness of 0.1 mm, (2) the adventitial volume (at 0.05 mm 
from the external elastic lamina {EEL]), and (3) the 
plaque + media volume located between the other two 
volumes.28329 The N U S  technique allows automated 
identification of the lumen-intima and the media-ad- 
ventitia boundaries. A three-dimensional reconstruc- 
tion of the above defined volumes is possible over the 
total length of the vessel segment to be irradiated, 
which in theory at least allows a calculation of the cu- 
mulative dose-volume frequency distribution on these 
predefined volumes. This DVH approach potentially 
offers the opportunity for a unique and universally ap- 
plicable definition of volumes of interest (VOI) and a 
uniform way of reporting dose distribution in pub- 
lished data (Table 2). Another refinement of dose pre- 
scription and reporting with this IVUS-based approach 
is the possibility of defining D,gOAdv (the minimal 
dose absorbed by 90% of the adventitial volume).31 
One of the assumptions made with this IVUS ap- 
proach is that the catheter of the ultrasound is in ex- 
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Table 2. Dose Specifications in the Randomized Trials for 
In-Stent Restenosis 
beta) could potentially be compared to obtain the best 
therapeutic 
START 90Sr/90Y < 20 mm 
In-stent restenosis 
WRIST I9’Ir < 47 mm 
In-stent restenosis 
GAMM-I I9*Ir < 45 mm 
In-stent restenosis 
SCRIPPS-I1 1921r < 30 mm 
In-stent restenosis 
16 or 20 Gy at 2 mm 
depending on 
vessel 4 
15 Gy at 2 mm 
(4 = 2 4  mm) 
15 Gy at 2.4 mm 
( 9 > 4 m m )  
8 Gy to target farthest 
from source but 
< 30 Gy closets to 
source 
8 Gy to target farthest 
from source but 
< 30 Gy closets to 
source 
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actly the same position as the catheter containing the 
source train, which is not necessarily the case. Other 
limitations of this IVUS technique are the image arti- 
facts due to cyclic changes in coronary dimensions and 
movement of the IVUS catheter in the arterial lumen3* 
Finally, the DVH cannot be used alone to evaluate the 
quality of the treatment and should be used in con- 
junction with a two-dimensional dose display to obtain 
information on the spatiality of the dose distributi01-1.~~ 
However, the strength of this approach based on DVH 
is that it allows screening of different treatment tech- 
niques, comparison, and real-time optimization of 
dose prescription. This leads potentially to inverse 
treatment planning, that is, automatic generation of a 
treatment plan based on the dosimetric intent, a tech- 
nique which is largely implemented in external radio- 
therapy in oncology.34 
It is currently known that the matched peripheral 
dose (MPD) concept, as used for the first time in inter- 
stitial brachytherapy in prostate cancer by Ander~on,~’ 
through a dimension averaging procedure (considering 
the volume to be an ellipsoid) and introduced de facto 
in vascular brachytherapy and the minimal dose at the 
periphery of the target are suboptimal ways of esti- 
mating the quality of the dosimetry. This approach 
does not offer any estimation of the dose inhomogene- 
ity within the target volume. Real-time dosimetry 
based on ultrasound imaging is certainly going to be 
possible in the near future and will allow a quantitative 
volumetric dosimetry analysis in the context of vascu- 
lar bra~hytherapy.~~ This is the first step to optimizing 
treatment as, in theory, different techniques (centered 
vs noncentered) and different isotopes (gamma versus 
1. Gruentzig AR. Transluminal dilatation of coronary artery 
stenosis. Lancet 1978; 1:263. 
2. Goy JJ, Eeckhout E. Intracoronary stenting. Lancet 1998; 
35 1: 1943-1949. 
3. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after 
successful percutaneous transluminal coronary angioplasty: 
Serial angiographic follow-up of 229 patients. J Am Coll Car- 
diol 1988; 12:616-623. 
Conclusion 
Optimal endovascular irradiation (i.e., maximizing 
the response rate while keeping the complication rate 
as low as possible) will require a more refined way of 
defining target volume and dose prescription than the 
one used in the published trials. Proponents of the 
simple approach (i.e., prescribing the dose at a fixed 
distance from the source) will argue that in the previ- 
ously published randomized clinical trials (WRIST, 
GAMMA I, SCRIPPS, and START trials) there is a 
statistically and clinically significant decrease in the 
in-stent restenosis rate even if no special effort was 
made for a unique and universally accepted defini- 
tion of the target volume, and even if there are major 
differences in dose prescription and reporting. How- 
ever, one should be aware that in radiation therapy 
there is always a therapeutic window, and therefore, 
special efforts should be made to apply standardized 
rules for target volume definition, dose prescription, 
and reporting to allow intercomparison between dif- 
ferent technical approaches. That is the price to pay 
for the increase of therapeutic efficacy and the reduc- 
tion of long-term complications. We are all aware 
that the inhomogeneous dose distribution is inherent 
to the brachytherapy technique, but the extent of the 
dose inhomogeneity should be kept as small as possi- 
ble to reduce the risk of late  complication^.^^.^^ 
Methods such as image acquisition through constant 
step pullback of the IVUS controlled by the electro- 
cardiogram (ECG) trigger algorithm with automatic 
real-time target delineation and three-dimensional re- 
construction combined to computerized dosimetry is 
certainly one of the ways to make progress in suc- 
cessful endovascular brachytherapy for the preven- 
tion of stenosis. 
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